The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

FDA vaccines chief Vinay Prasad limited broader use of COVID vaccines, citing reduced risk and data concerns. Read more here.

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said ...

The agency's website indicates HHS Secretary Robert F. Kennedy Jr. adopted the previous advisory panel's suggestion to expand access on June 25. AP also reports on FDA vaccine chief Vinay Prasad's ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The U.S. FDA approved 14 drugs in May, a decline from 20 in April and 22 in March. That brings the year-to-date total for 2025 to 84 approvals, the second highest on record for this period, just ...